Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 8,117,000 | 8,012,000 | 7,884,000 | 7,363,000 | 8,052,000 |
| Cost of Goods | 2,559,000 | 2,397,000 | 2,122,000 | 1,970,000 | 2,418,000 |
| Gross Profit | 5,558,000 | 5,615,000 | 5,762,000 | 5,393,000 | 5,634,000 |
| Operating Expenses | 3,341,000 | 5,426,000 | 4,116,000 | 3,903,000 | 4,461,000 |
| Operating Income | 2,217,000 | 189,000 | 1,646,000 | 1,490,000 | 1,173,000 |
| Interest Expense | 144,000 | 156,000 | 174,000 | 166,000 | 155,000 |
| Other Income | -1,510,000 | 31,000 | 23,000 | 31,000 | -639,000 |
| Pre-tax Income | 563,000 | 64,000 | 1,495,000 | 1,355,000 | 379,000 |
| Income Tax | 62,000 | -1,000 | 191,000 | 274,000 | -19,000 |
| Net Income Continuous | 501,000 | 65,000 | 1,304,000 | 1,081,000 | 398,000 |
| Minority Interests | -87,000 | -123,000 | -131,000 | -35,000 | -48,000 |
| Net Income | $414,000 | $-58,000 | $1,173,000 | $1,046,000 | $350,000 |
| EPS Basic Total Ops | 0.10 | -0.01 | 0.29 | 0.26 | 0.09 |
| EPS Basic Continuous Ops | 0.10 | -0.01 | 0.29 | 0.26 | 0.09 |
| EPS Diluted Total Ops | 0.10 | -0.01 | 0.29 | 0.25 | 0.09 |
| EPS Diluted Continuous Ops | 0.10 | -0.01 | 0.29 | 0.25 | 0.09 |
| EBITDA(a) | $1,119,000 | $1,171,000 | $2,308,000 | $2,070,000 | $1,157,000 |